European Commission Vice-President Günter Verheugen has called for the revival of the stalled directive on providing information to patients, which has been held up by EU health ministers.
Speaking to the European Parliament’s environment committee, which deals with public health issues, Verheugen acknowledged that progress on the directive is unlikely to come before the end of the year, saying it had proven to be a “difficult and very emotional” issue.
He said breaking the impasse at European ministerial level would fall on Spain, which takes over the six-month rotating EU presidency in January. The Swedish Presidency is currently focusing on securing agreement on counterfeit medicines and pharmacovigilence while disagreements over the Information to Patients Directive rumble on.
Current policy in this area is being influenced by the decisions of the European Court of Justice and politicians should be concerned by this, the commissioner said.
Verheugen, whose responsibility for enterprise policy includes medicines, said he was “more convinced than ever” of the necessity of updating rules on communicating to patients about medicines. “This isn’t based on the interests of the pharmaceutical industry. It’s based on supporting patients.”
He said the Commission was proposing a “controlled step” forward which would embrace advances in information technology, and berated the medicine industry for dubious marketing practices.
“It is necessary to have a clear border between information and advertising. In the pharma industry there are marketing practices which are not acceptable. The ban on advertising is being circumvented by industry which is exploiting a grey area. In print and online media there are contributions behind which are the interests of the industry – but the patient doesn’t know it because it is hidden.”
He said a code of conduct would be necessary to curb questionable information campaigns conducted by pharmaceutical companies. “We want to protect patients from hidden advertising,” he said.
Verheugen told MEPs there had been significant progress on tackling the growing problem of counterfeit medicines. “I don’t envisage any problems with this but I would hope it can be wrapped up as soon as possible so that the pharmaceutical industry knows what’s ahead.”
Ministers are expected to discuss the issue at a meeting in Brussels in December and may be in a position to reach agreement on counterfeit medicines. EU sources indicated that ministers are not satisfied with the Commission’s proposal on information to patients as it stands, but could return to the issue if the proposal is amended.
The legislation will be decided upon jointly by MEPs and EU governments, and member states are watching closely for developments in the European Parliament.